Loading...
Bienvenue sur la collection HAL du laboratoire de BECCOH
Quelques conseils pour une publication "idéHALe"
• Pensez à respecter la signature institutionnelle
Université Paris-Saclay, UVSQ, BECCOH, 92104, Boulogne-Billancourt, France..
• Participez à l'accès ouvert
N'attendez pas : dès que votre article est en ligne, déposez dans Hal sa version acceptée pour publication et indiquez un embargo de 6 mois.
La loi pour une république numérique vous autorise en effet à partager cette version 6 mois après publications, quelque-soit l'éditeur
Plus d'informations Archives Ouverte : quid de mes droits d'auteurs ?
• Vous souhaitez disposer d'une page web référençant toutes vos publications ?
Créez vous en 5 minutes un idHal et un CVHAL
N'hésitez pas à nous contacter pour toutes questions,
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
Dernières Publications en accès ouvert dans Hal
-
Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, et al.. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2024, 188, pp.107447. ⟨10.1016/j.lungcan.2023.107447⟩. ⟨hal-04517531⟩
-
Johanne Seguin, Mostafa El Hajjam, Josette Legagneux, Sarah Diakhaby, Nathalie Mignet, et al.. Radiofrequency Combined with Intratumoral Immunotherapy: Preclinical Results and Safety in Metastatic Colorectal Carcinoma. Pharmaceutics, 2024, 16 (3), pp.315. ⟨10.3390/pharmaceutics16030315⟩. ⟨hal-04626840⟩
-
Alexandra Kachaner, Raphaèle Seror, Fleur Cohen Aubart, Julien Henry, Thierry Lazure, et al.. Complete remission after a single bisphosphonate infusion in isolated bone Langerhans cell histiocytosis lesion: a case report and a narrative review of the literature. JBMR Plus, 2024, 8 (5), pp.ziae043. ⟨10.1093/jbmrpl/ziae043⟩. ⟨hal-04626829⟩
-
Robin Zagala, Nicolas Meyer, Philippe Saiag, Nora Kramkimel, Celeste Lebbe, et al.. Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network. Journal of the European Academy of Dermatology and Venereology, In press, ⟨10.1111/jdv.20155⟩. ⟨hal-04626767⟩
-
Julie Lecuelle, Caroline Truntzer, Debora Basile, Luigi Laghi, Luana Greco, et al.. Machine learning evaluation of immune infiltrate through digital tumour score allows prediction of survival outcome in a pooled analysis of three international stage III colon cancer cohorts. EBioMedicine, 2024, 105, pp.105207. ⟨10.1016/j.ebiom.2024.105207⟩. ⟨hal-04626841⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. European Journal of Cancer, 2023, 193, pp.113252. ⟨10.1016/j.ejca.2023.113252⟩. ⟨inserm-04209605⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023. European Journal of Cancer, 2023, 193, pp.113251. ⟨10.1016/j.ejca.2023.113251⟩. ⟨inserm-04210036⟩
Mots clés
Follow-up
Cemiplimab
Children
Anti-PD-1 antibody
Langerhans cell histiocytosis
Colon cancer
Radiotherapy
Targeted therapy
Assisted reproductive techniques
Advanced
AZD9291
Allelic imbalance
Diagnosis
TNM classification
Trametinib
Polyomavirus
Cutaneous squamous cell carcinoma
BRAFV600-mutant melanoma
Histiocytosis
Oncology
Circulating cell-free DNA
Body mass index
Radiofrequency ablation
Abdominal pain
Metastatic cSCC
Metastatic
Melanoma
Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy
Immunomodulation
Antibody-drug conjugate
Anti-PD1 blockade
Cancer
Crizotinib
EGFR
Prevention
2-chlorodeoxyadenosine
Prognosis
Merkel cell carcinoma
Biliopancreatic diversion
Molecular targeted therapies
Biomarkers
BRAF V600E
Nivolumab
Treatment
Cancer bronchique non à petites cellules
Anti-PD-1
Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian
BRAFV600E
Bisphosphonates
Beta-catenin
Anti-PD1
Lung adenocarcinoma
Dabrafenib
Safety
Osimertinib
Androgen insensitivity
Bariatric surgery
Anti-Tumor pharmacology
Abscopal effect
BRAFV600E mutation
Circulating tumor DNA
Biomarker
Systemic therapy
Liver metastases
Immunohistochemistry
ADN tumoral circulant
Adjuvant
Plasma
Locally advanced
ALK
Chemoresistance
Mesenchymal stromal cells
Adverse events
Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation
Gastric bypass
Staging
Adjuvant therapy
Colorectal cancer
Immune checkpoint inhibitor
Colorectal carcinoma
BRAF
Chemotherapy
Resistance
Adjuvant FOLFOX
Acute generalized exanthematous pustulosis
Sonic Hedgehog
Anti-CTLA-4
Advanced melanoma
Surgical excision
ALK rearrangement
Survival
ACTH
Antineoplastic agents
Immunotherapy
Non-small cell lung cancer
BRAF V600-mutation
Wnt
Prognostic
AML
Invasive cutaneous squamous cell carcinoma